Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CompumedicsASX:CMP 55 EV-to-Revenue is 1.10 as of Aug. 26, 2026, which is 37% below its 10-year median of 1.75. GuruFocus rates ASX:CMP with a GF Score™ of 55/100 and a GF Value™ of A$0.32 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Compumedics ranks better than 79.75% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Compumedics's enterprise value is A$64.33 Mil.
Compumedics's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was A$58.28 Mil. Therefore, Compumedics's EV-to-Revenue for today is 1.10.
The historical rank and industry rank for Compumedics's EV-to-Revenue or its related term are showing as below:
ASX:CMP'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.39 Med: 1.75 Max: 3.99
Current: 1.1
During the past 13 years, the highest EV-to-Revenue of Compumedics was 3.99. The lowest was 0.39. And the median was 1.75.
ASX:CMP's EV-to-Revenue is ranked better than 79.75% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 2.99
vs ASX:CMP: 1.10
As of today (2026-08-26), Compumedics's stock price is A$0.265.
Compumedics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.30. Therefore, Compumedics's PS Ratio for today is 0.89.
Compumedics's share price for today is A$0.265.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2025 was A$0.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compumedics EV-to-Revenue Related Terms
Compumedics EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Compumedics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMP vs ABT, SYK, MDT: EV-to-Revenue Comparison
For the Medical Devices subindustry, Compumedics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compumedics EV-to-Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Compumedics's EV-to-Revenue falls into.
Compumedics's current Enterprise Value is A$64.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Compumedics's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was A$58.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compumedics (ASX:CMP) has a EV-to-Revenue of 1.10 as of Aug. 26, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Compumedics and its competitors. This is 37% below median its historical median of 1.75. Over the past decade, Compumedics' EV-to-Revenue has ranged from 0.39 to 3.99. According to the industry distribution chart, Compumedics ranks #165 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 20.2%.
Is Compumedics' EV-to-Revenue too high?
Compumedics' current EV-to-Revenue of 1.10 is 37% below median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 3.99. The Medical Devices & Instruments industry median EV-to-Revenue is 2.99. Compumedics' value of 1.10 is 63.2% below this industry median. Based on the distribution chart, Compumedics ranks #165 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Compumedics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' EV-to-Revenue compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #165 out of 815 companies for EV-to-Revenue. This places Compumedics in the top 20% of its industry — outperforming the majority of peers. The industry median EV-to-Revenue is 2.99. Compumedics' value of 1.10 is 63.2% below this benchmark. Historically, Compumedics' own EV-to-Revenue has ranged from 0.39 to 3.99 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 2.99, Compumedics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Medical Devices & Instruments company?
The median EV-to-Revenue among Medical Devices & Instruments companies is 2.99, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compumedics's current EV-to-Revenue of 1.10 is 63.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Compumedics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-Revenue is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current EV-to-Revenue is 1.10, which is 37% below median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.32, compared to a current price of A$0.27 — trading 17.2% below its estimated fair value. The current EV-to-Revenue is 1.10, which is 37% below median its 10-year median of 1.75 and 63.2% below the Medical Devices & Instruments industry median of 2.99. Compumedics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current EV-to-Revenue is 1.10 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compumedics (ASX:CMP) Overvalued in 2026?
Based on GuruFocus' analysis, Compumedics stock appears to be undervalued.
The current stock price of A$0.27 is trading 17.2% below its estimated GF Value™ of A$0.32.
GuruFocus considers Compumedics to be Modestly Undervalued.
Key valuation signals for ASX:CMP:
EV-to-Revenue: 1.10 (37% below median its 10-year median of 1.75)
GF Value™: A$0.32 vs. price of A$0.27 (17.2% below fair value)
Industry Position: 63.2% below the Medical Devices & Instruments median (#165 of 815)
No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
55GF Score
Get the complete analysis for ASX:CMP
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMP has been successfully added to your 
